Pharmacognostic and Acute Toxicity Study of Burkea Africana Root

Burkea africana is a plant that belongs to then family Fabaceae; it is widely spread in tropical Africa including Nigeria. It is of valuable in  ethnomedicine especially in the treatment of antidote for venomous stings and bites, cutaneous and sub cutaneous parasitic infection, convulsion and pulmonary troubles. Despite the fact that roots of Burkea africana have several medicinal properties, no standardization parameter has been  assessed. Due to lack of standard parameters, proper identification and ascertaining quality and purity in the events of adulteration has been thwarted. The objective of the study was to establish some important pharmacognostic profile and safety margin of Burkea africana root with the hope of assisting in its standardization for quality, purity and safety. Elemental analysis was carried out using acid digestion method and phytochemical composition of the plants was evaluated using standard method. Acute toxicity was achieved using Lorke method to determine the LD50. Chemomicroscopical evaluation revealed the presence of cellulose, tannins, starch, lignin, calcium oxalate, suberin, aleurone grain and mucilage with the exception of calcium carbonate. The average moisture contents, total ash, acid insoluble, water soluble ash, alcohol extractive value and water extractive values in the powdered plant material were 3.8%, 7.5%, 4.43%, 8.07%, 25.0% and 20.33% respectively. In addition, Fe, Mn, Ni, Pb, Cd and Cu were found to be within the safety limit. Phytochemicals which include alkaloids, flavonoids, saponins, tannins, carbohydrates and triterpenes were detected in both aqueous and methanolic extracts. The LD50 of Burkea africana was found to be greater than 5000 mg /kg and could be considered safe for consumption. Keywords: Elemental analysis, Burkea africana, Pharmacognostic, Phytochemica

The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. METHODS: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. FINDINGS: Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). INTERPRETATION: The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden

Influence of Allium Sativum (Garlic), Zingiber officinale (Ginger) and Syzygium aromaticum (Clove) Extract against Larvae of Aedes mosquitoes (Culicidae: Diptera)

Mosquito control has become more difficult due to the unsystematic use of synthetic chemical insecticides which have inauspicious effect on the environment. Botanical phyto-chemicals with mosquitocidal potential are now recognized as potent alternative insecticides to replace synthetic insecticides in mosquito control programs due to their excellent larvacidal activities. The present study assessed the influence of A. sativum (garlic), Z. officinale (ginger) and S. aromatic (clove) extracts against Aedes mosquitoes. Larvacidal activities of three indigenous plant extracts were studied in the range 5.0 to 30.0mg/l in the laboratory bioassay against fourth instar larvae of Aedes sp. The mortality were subjected to probit analysis to determine the lethal concentration (LC50) to kill 50 percent of treated larvae of Aedes sp. Data obtained were analyzed by Comparing experimental groups and control groups with significance level established at p<0.05. All plants tasted showed effects after 24hrs of exposure at different concentration (mg/l). However the highest mortality was found in A. Sativum (garlic) and Z. officinale (ginger) against larvae of Aedes mosquitoes with LC50 = 42.50% (2.685) and LC50 = 30.01% (4.461) mg/l, while S. aromatic(clove) was found to have lowest mortality at LC50 = 24.50% (5.52) respectively. It is therefore recommended that A. sativum(Gallic), S. aromatic (Clove) has showed larvacidal effects against Aedes mosquitoes and could be served as alternative form of botanical control against mosquitoes . Keywords: A. sativum (garlic), Z. officinale (ginger) and S. aromatic (clove), Extracts, Aedes mosquitoe

Pharmacognostic, elemental and acute toxicity study of Fadogia agrestis root

An aphrodisiac is a type of food or drink that has the effect of making those who eat or drink it more aroused in a sexual way. Aphrodisiacs can be categorized according to their mode of action into three groups: substances that increase libido (i.e. sexual arousal), substances that increase sexual potency (i.e. effectiveness of erection) and substances that increase sexual pleasure. Fadogia agrestis (Schweing. Ex. Hiern), Rubiacea (Hausa: Bakin gagai; English name: Black aphrodisiac) is an erect shrub 1-3 feets high. Fadogia agrestis is a medicinal plant widely used for its reported antibacterial and aphrodisiac activities. The aim of this work is to carry out pharmacognostic standardization and safety profile on Fadogia agrestis root. Chemomicroscopic, physicochemical, elemental, phytochemical and acute toxicity studies were carried out using standard methods. The results obtained also provided scientific basis for the use of in folklore medicine. Chemomicroscopic characters present include; cellulosecell wall, lignified cell wall, tannins, starch, calcium oxalate and cutin. The physicochemical parameters evaluated include: moisture content (7.0%), total ash (10.5%), water soluble ash (4.1%), acid insoluble ash (8.33%), ethanol extract (15.0%), and water extractive value (12.0%). The quantitative phytochemical analysis showed that alkaloids (84.0 mg/g) was the highest phytochemical detected in the stem bark while the lowest was saponins (4.0 mg/g).LD50 of both extracts was above 5000 mg/kg and did not cause mortality in all the tested rats. The results of this investigation may be useful for deriving doses that are safe for human consumption of F. agrestis root.&nbsp

Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

Importance: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. Objective: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. Evidence Review: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95 uncertainty intervals (UIs). Findings: In 2019, there were an estimated 23.6 million (95 UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95 UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3 (95 UI, 20.3-32.3) increase in new cases, a 20.9 (95 UI, 14.2-27.6) increase in deaths, and a 16.0 (95 UI, 9.3-22.8) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4 (1.1-1.8) in the low SDI quintile to 5.7 (4.2-7.1) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. Conclusions and Relevance: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.. © 2021 American Medical Association. All rights reserved

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15–39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15–39 years to define adolescents and young adults. Findings There were 1·19 million (95% UI 1·11–1·28) incident cancer cases and 396 000 (370 000–425 000) deaths due to cancer among people aged 15–39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59·6 [54·5–65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8–57·9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9–15·6] per 100 000 person-years) and middle SDI (13·6 [12·6–14·8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23·5 million (21·9–25·2) DALYs to the global burden of disease, of which 2·7% (1·9–3·6) came from YLDs and 97·3% (96·4–98·1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts